Apollomics, Inc. (APLM)
NASDAQ: APLM · Real-Time Price · USD
9.75
+0.35 (3.72%)
At close: Dec 20, 2024, 4:00 PM
9.24
-0.51 (-5.23%)
After-hours: Dec 20, 2024, 7:00 PM EST
Apollomics Revenue
Apollomics had revenue of $1.77M in the half year ending June 30, 2024, with 197.14% growth. This brings the company's revenue in the last twelve months to $2.10M, up 70.54% year-over-year. In the year 2023, Apollomics had annual revenue of $821.00K with 154.18% growth.
Revenue (ttm)
$2.10M
Revenue Growth
+70.54%
P/S Ratio
4.26
Revenue / Employee
$46,689
Employees
45
Market Cap
10.75M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 821.00K | 498.00K | 154.18% |
Dec 31, 2022 | 323.00K | 321.00K | 16,050.00% |
Dec 31, 2021 | 2.00K | -1.84M | -99.89% |
Dec 31, 2020 | 1.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPLM News
- 1 day ago - Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 11 days ago - Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 3 months ago - Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - GlobeNewsWire
- 4 months ago - Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - GlobeNewsWire
- 5 months ago - Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 6 months ago - Apollomics Announces Updated Strategic Focus and Leadership Team Changes - GlobeNewsWire
- 8 months ago - Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene - GlobeNewsWire